Christophe Passot Selected Research

Christophe Passot Research Topics

4	Rheumatoid Arthritis 01/2022 - 11/2015
2	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 02/2018
2	Crohn Disease (Crohn's Disease) 01/2022 - 10/2016
2	Ankylosing Spondylitis 01/2022 - 10/2016
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2021 - 11/2020
2	Neoplasm Metastasis (Metastasis) 01/2021 - 11/2020
1	Body Weight (Weight, Body) 02/2024
1	Necrosis 01/2022
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/2021
1	Rare Diseases (Rare Disease) 01/2021
1	Peritoneal Neoplasms 11/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2020
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2019
1	Hemolysis 01/2019
1	Headache (Headaches) 01/2018
1	Neck Pain (Cervicalgia) 01/2018
1	Vomiting 01/2018
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2018
1	Meningeal Carcinomatosis 01/2018
1	Nausea 01/2018
1	Chronic Disease (Chronic Diseases) 10/2016
1	Ulcerative Colitis 10/2016
1	Psoriatic Arthritis 10/2016
1	Virus Diseases (Viral Diseases) 05/2015
1	Neoplasms (Cancer) 01/2012
1	Parasitic Diseases (Parasitic Disease) 01/2012

7	Monoclonal AntibodiesIBA 01/2022 - 11/2015
3	Infliximab (Remicade)FDA Link 01/2022 - 10/2016
2	eculizumab FDA Link 02/2024 - 01/2021
2	Immunoglobulins (Immunoglobulin)IBA 01/2023 - 01/2019
2	AerosolsIBA 01/2021 - 11/2020
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 11/2020
2	Immunoglobulin G (IgG)IBA 01/2017 - 05/2015
1	Cetuximab (Erbitux)FDA Link 01/2023
1	ErbB Receptors (EGF Receptor)IBA 01/2023
1	Tyrosine Kinase InhibitorsIBA 09/2020
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 09/2020
1	Inosine Triphosphate (ITP)IBA 01/2019
1	RHO(D) antibody (anti-D)IBA 01/2019
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2019
1	Rho(D) Immune Globulin (RhoGAM)IBA 01/2019
1	Panitumumab (Vectibix)FDA Link 02/2018
1	Trastuzumab (Herceptin)FDA Link 01/2018
1	Rituximab (Mabthera)FDA Link 01/2017
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2016
1	neonatal Fc receptorIBA 05/2015
1	Alemtuzumab (Campath)FDA Link 01/2012

1	Aftercare (After-Treatment) 01/2022
1	Drug Therapy (Chemotherapy) 11/2020